Rick Doblin

Founder, Multidisciplinary Association for Psychedelic Studies (MAPS)

Appears in 1 story

Stories

Federal psychedelic therapy policy shifts from prohibition to expedited research

As of May 2026: Continuing advocacy after FDA's 2024 MDMA rejection

For 55 years, the federal government classified psilocybin, MDMA, LSD, and ibogaine as Schedule I substances. On April 18, 2026, President Trump signed an executive order 'Accelerating Medical Treatments for Serious Mental Illness' directing the FDA to expedite clinical trials of those substances for PTSD in veterans.

Updated May 31